National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Apremilast (Otezla®) for moderate to severe chronic plaque psoriasis.

Indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to systemic non-biologic therapies including cyclosporine, methotrexate or psoralen and ultraviolet A light (PUVA).

Rapid Review

Commenced Completed Outcome
24/02/2015 03/04/2015 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
28/07/2015  27/01/2016 Reimbursement Not Recommended at the Submitted Price.

Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.